Company intelligence / Profile preview

HC Biopharma

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Currently conducting Phase 1 study (NCT06307925) to evaluate safety, pharmacokinetics and antitumor activity of HC010 in patients with advanced solid tumors

Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

HC010

Phase 1

Indications: Advanced solid tumors, Non-small cell lung cancer, Hepatocellular carcinoma, Colorectal cancer, Cervical cancer

Beyond the preview

Go deeper on HC Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HC Biopharma.

Explore the full profile